US Patent 7201913 Oral formulations for anti-tumor compounds
Patent 7201913 was granted and assigned to Pfizer on April, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 6 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Alessandro Martini0
Christopher James0
Lorena Muggetti0
Paola Civaroli0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+325 characters)
Article
Patent abstract
The present invention relates to a semi-solid filling medium which comprises a camptothecin derivative; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilizing-promoting amount of one or more pharmaceutically acceptable excipients.
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07201913 Oral formulations for anti-tumor compounds US Patent 7201913 Oral formulations for anti-tumor compounds
Infobox
Patent Number
072019130
Patent Number
72019130
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072019130
Date of Patent
April 10, 2007
0Patent Application Number
101102250
Date Filed
October 2, 2000
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 20 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07201913 Oral formulations for anti-tumor compounds
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07201913
Date of patent
April 10, 2007
Patent application number
10110225
Date Filed
October 2, 2000
Patent primary examiner
Find more entities like US Patent 7201913 Oral formulations for anti-tumor compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
